Last reviewed · How we verify
NCT04826432: PASIREOCHIP
Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis
Phase 2 trial testing Pasireotide 0.9 MG/ML in Peritoneal Carcinomatosis in 6 participants. Terminated before completion.
7 February 2024
Quick facts
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 3 September 2020 |
| Primary completion | 7 February 2024 |
| Estimated completion | 7 February 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Pasireotide 0.9 MG/ML — full drug profile →
- Saline water
Conditions studied
- Peritoneal Carcinomatosis — all drugs for Peritoneal Carcinomatosis →
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris — full company profile →
Who can join
Adults 18 to 75, any sex, with Peritoneal Carcinomatosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative digestive leakage after CRS plus HIPEC compared to placebo
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04826432
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pasireotide 0.9 MG/ML
Trials testing the same drug.
- NCT04281680 — Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections · completed
Other recruiting trials for Peritoneal Carcinomatosis
Currently open trials in the same condition.
- NCT04107077 — Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advance · Phase 2 · recruiting
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT06929013 — Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer. · NA · recruiting
- NCT07514494 — Intensification Treatment of Ovarian Cancer by PIPAC · Phase 2 · recruiting
- NCT07493876 — Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With · NA · recruiting
Other Gustave Roussy, Cancer Campus, Grand Paris trials
Trials by the same sponsor.
- NCT07303387 — Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. · Phase 2 · not yet recruiting
- NCT07159451 — A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovaria · Phase 2 · recruiting
- NCT06781996 — A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuva · Phase 3 · recruiting
- NCT07016230 — Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and · Phase 2 · recruiting
- NCT06902883 — Study on the Effectiveness and Comfort of Innovative Solutions for the Internal Transport of Patients in Wheelchairs in · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04826432 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gustave Roussy, Cancer Campus, Grand Paris
- Last refreshed: 8 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04826432.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing